entertainment -WSS

entertainment

author：knowledge 2025-09-29 16:44:46 - browse：517

Maze Therapeutics CEO Jason Coloma Courtesy

After seeing its last deal go bust in the face of regulatory scrutiny, Maze Therapeutics has found another suitor for its experimental Pompe disease treatment.

Bay Area-based Maze and Shionogi said Friday that the Japanese pharma company had licensed the drug, called MZE001, with an upfront payment of $150 million. The global deal includes additional, undisclosed payments if the oral medication, which is in clinical testing, meets certain regulatory and commercial goals.

Last year, Sanofi, the French pharma giant, was set to pay $150 million in cash and stock to Maze before the transaction fell apart.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Protect nursing home residents from future pandemics

knowledge

WSS

FDA approves potent Eli Lilly obesity drug, Zepbound

Removing probiotics from the NICU could threaten preemies' health

Just how powerful is the placebo effect?

Biotech incubator Curie.Bio graduates its first startup

Some medical students still think black patients feel less pain

MoonLake credibility takes another hit with mid

knowledge

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

In Memoriam: Notable people who died in 2023

New research sheds light on how often breast cancer is overdiagnosed

In age of alternative facts, a scholarly course on calling out crap

Ozempic cut risk of death in diabetes patients with chronic kidney disease

After affirmative action ruling, medical educators look to 'holistic review'

Medical students need to learn the potent medicine of empathy

Medical records are filled with copy

Beyond aggravation: Constipation is an American epidemic

New air purifier tech could be key to improving indoor air quality

White House calls on federal agencies to crack down on AI abuses

leisure time

Diversify hospital leadership teams to protect BIPOC patient health

Medicare solvency divides Republicans at the presidential debate

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

10 million people disenrolled from Medicaid over past six months

Senate panel clears PBM, hopsital reforms

Asahi Kasei to buy Calliditas, picking up kidney disease drug

explore

knowledge

explore

entertainment